-
Cumberland Pharmaceuticals announced positive cardiac results from Phase 2 trial in Duchenne
Cumberland Pharmaceuticals announced positive cardiac results from Phase 2 trial in Duchenne Cumberland Pharmaceuticals released positive top-line results from its Phase 2 FIGHT DMD trial, a 12-month placebo controlled study evaluating Ifetroban in 41 individuals with DMD. Individuals who received either low or high dose Ifetroban daily showed improvements in their heart’s left ventricular ejection…
-
Entrada Therapeutics gets ok to start Exon 44 skipping trial in UK
As an early funder of Entrada, CureDuchenne is pleased to share that Entrada received authorization in the United Kingdom (UK) to start a Phase 1/2 trial for individuals with Duchenne amenable to exon 44 skipping. Part A, which is planned to start in Q2 2025, will be a multiple-ascending dose study in 24 individuals with…
-
To a parent, the years always seem too short
I read a quote the other day on Facebook: “When you are raising babies, you feel how long the days are. When raising teens, you feel with every single bone in your body how short the years are.” Days later, I still carry those words with me as a mom of seven children: Lexi, 23;…
-
CureDuchenne Announces Educational Events for Families and Caregivers of Individuals with Duchenne or Becker Muscular Dystrophy
Upcoming Events Offer Treatment Updates and Essential Resources to Support Families and Enhance Quality of Life NEWPORT BEACH, Calif., January 31, 2025 – CureDuchenne, a global leader in advancing research and patient care for individuals with Duchenne and Becker muscular dystrophy, is proud to announce its 2025 schedule of events for families and caregivers. These events…
